151751-Najiba-Chargi

354 CHAPTER 17 41. Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A. Patient-re - ported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyn- geal cancer: Prospective longitudinal study. Int J Radiat Oncol Biol Phys . 2014;89(5):973- 980. doi:10.1016/j.ijrobp.2014.03.013 42. Jacobi I, Van Rossum MA, Van Der Molen L, Hilgers FJM, Van Den Brekel MWM. Acoustic analysis of changes in articulation proficien- cy in patients with advanced head and neck cancer treated with chemoradiotherapy. Ann Otol Rhinol Laryngol . 2013;122(12):754- 762. doi:10.1177/000348941312201205 43. Chargi N, Bril SI, Swartz JE, Wegner I, Wil - lems SW, de Bree R. Skeletal muscle mass is an imaging biomarker for decreased sur- vival in patients with oropharyngeal squa- mous cell carcinoma. Oral Oncol . 2020;101. doi:10.1016/j.oraloncology.2019.104519 44. Vangelov B, Kotevski DP, Williams JR, Smee RI. The impact of HPV status on weight loss and feeding tube use in oropharyngeal carcinoma. Oral Oncol . 2018;79:33-39. doi:10.1016/j.oraloncology.2018.02.012 45. Vatca M, Lucas JT, Laudadio J, et al. Ret - rospective analysis of the impact of HPV status and smoking on mucositis in pa- tients with oropharyngeal squamous cell carcinoma treated with concurrent che- motherapy and radiotherapy. Oral Oncol . 2014;50(9):869-876. doi:10.1016/j.oralon - cology.2014.06.010 46. Sharma A, Méndez E, Yueh B, et al. Human papillomavirus-positive oral cavity and oropharyngeal cancer pa- tients do not have better quality-of-life trajectories. Otolaryngol - Head Neck Surg (United States) . 2012;146(5):739-745. doi:10.1177/0194599811434707